

87028_Auto_Edited.docx

Name of Journal: *World Journal of Biological Chemistry*

Manuscript NO: 87028

Manuscript Type: ORIGINAL ARTICLE

Basic Study

Protein Arginine Methyltransferase 6 (PRMT6) is a Novel Substrate of Protein Arginine Methyltransferase 1 (PRMT1)

Mechanism of PRMT1-PRMT6 Interaction

Mengtong Cao, You Feng, Y. George Zheng

Abstract

BACKGROUND

Post-translational modifications (PTMs) play key roles in various biological processes. Protein arginine methyltransferases (PRMTs) transfer the methyl group to specific arginine residues. Both PRMT1 and PRMT6 have emerged as crucial factors in the development and progression of multiple cancer types. We posit that Protein arginine methyltransferase 1 (PRMT1) and Protein arginine methyltransferase 6 (PRMT6) might interplay directly or in-directly in multiple ways accounting for shared disease phenotypes.

AIM

The aim of this study is to investigate the mechanism of the interaction between PRMT1 and PRMT6.

METHODS

Gel electrophoresis autoradiography was performed to test the methyltransferase activity of PRMTs and characterize the kinetics parameters of PRMTs. LC-MS/MS analysis was performed to detect the PRMT6 methylation sites.

RESULTS

In this study we investigated the interaction between PRMT1 and PRMT6, and PRMT6 was shown to be a novel substrate of PRMT1. We identified specific arginine residues of PRMT6 that are methylated by PRMT1, with R106 being the major methylation site. Combined biochemical and cellular data showed that PRMT1 downregulates the enzymatic activity of PRMT6 in histone H3 methylation.

CONCLUSION

PRMT6 is methylated by PRMT1 and R106 is a major methylation site induced by PRMT1. PRMT1 methylation suppresses the activity of PRMT6.

Key Words: Posttranslational modification; arginine methylation; Protein arginine methyltransferase 1; protein arginine methyltransferase 6; cross-talk; protein-protein interaction.

Cao M, Feng Y, Zheng YG. Protein Arginine Methyltransferase 6 (PRMT6) is a Novel Substrate of Protein Arginine Methyltransferase 1 (PRMT1). *World J Biol Chem* 2023; In press

Core Tip: We reported the interplay between PRMT1 and PRMT6, and PRMT6 is a substrate of PRMT1. This study is important for understanding the cross-talking relationship between different protein arginine methyltransferases (PRMTs).

INTRODUCTION

Protein arginine methylation is a widespread post-translational modification (PTM) that regulates various biological processes in cellular physiology [1, 2]. Protein arginine methyltransferases (PRMTs) act as the controller of arginine methylation that transfers the methyl group from S-adenosyl methionine (SAM, AdoMet) to specific arginine residues on histone or nonhistone protein substrates [3-6]. The PRMT members are categorized into three types according to the stereochemical specificity of their product [7, 8]. The type I enzymes (PRMT1, PRMT2, PRMT3, CARM1, PRMT6, and PRMT8) catalyze the formation of ω -NG-monomethyl arginine (MMA) and ω -N^G, N^G-asymmetric dimethylarginine (ADMA) [9, 10]. The type II enzymes (PRMT 5 and PRMT9) catalyze the formation of MMA and ω -N^G, N^G-symmetric dimethylarginines (SDMA) [11, 12]. PRMT7 belongs to the type III enzyme and exclusively generates MMA [13].

Upregulation of PRMTs expression level is commonly observed in clinical oncology and is correlated with poor prognosis of patients [14-17]. Therefore, PRMTs emerge as potential novel molecular targets in cancer therapy development [18-21]. PRMT1 and PRMT6 both belong to the Type I PRMT family and the activities of PRMT1 and PRMT6 have been associated with distinct cellular functions. PRMT1 contributes to most of the ADMA in proteins [22] and plays key roles in regulating such biological processes as transcriptional regulation, signal transduction, cell proliferation, DNA damage repair owing to its action on numerous histone and non-histone substrates. On the chromatin, PRMT1 generates ADMA marks on histone H4R3, H2AR3, and H2AR11 [23-25]. Currently, seven PRMT1 isoforms (PRMT1-v1 to v7) have been identified: PRMT1-v1 and PRMT1-v7 are predominantly located in the nucleus, while PRMT1-v2 is primarily situated in the cytoplasm [26]. In gene expression regulation, PRMT1 is an activating transcription cofactor [27]. PRMT6 is another type-I PRMT member and is involved in a broad spectrum of biological and pathological processes, such as transcriptional regulation, DNA repair, cell movement, embryonic stem cell pluripotency, human immunodeficiency virus pathogenesis, and cardiovascular-associated diseases [28-33]. PRMT6 generates ADMA modifications on

H2AR29, H3R2, H3R17 and H3R42 [30, 34-39]. When PRMT6 adds H3R2me2a to the promoters, it suppresses transcription; however, when H3R2me2a is added to enhancers, PRMT6 promotes transcription [40]. The subcellular localization analysis shows PRMT6 is predominantly present in the nucleus [41].

Both PRMT1 and PRMT6 have emerged as crucial factors in the development and progression of multiple cancer types such as breast cancer, colorectal cancer, lung cancer, and bladder cancer. Notably, experimental knockdown of PRMT1 and PRMT6 using siRNAs has been shown to significantly inhibit the growth of bladder and lung cancer cells [42]. The tumor-promoting roles of PRMT1 and PRMT6 in oncology are executed through their methylation of histone and non-histone substrates [42-46]. Expression profile analysis suggests that PRMT1 and PRMT6 are both involved in multiple pathways which are fundamental for cell proliferation [42]. We posit that PRMT1 and PRMT6 might interplay directly or in-directly in multiple ways accounting for shared disease phenotypes. Thereby, neutralizing these enzymes' activities or their interactions may interfere with tumor progression and lead to anticancer beneficial effects.

The structural analysis of PRMTs using X-ray crystallography has revealed a consistent homodimeric structure across all the type I PRMT isoforms, representing the active unit for their catalytic activity [47-49]. PRMT5 homodimer is further extended into a hetero-octameric state with MEP50 included in the complex [50]. In addition to homodimerization, several studies have provided evidence for the existence of PRMTs heterological complex formation with other PRMT members. For instance, Frankel *et al* found that PRMT1 forms heterodimers or oligomers with PRMT2, and this interaction synergistically enhances the catalytic activities of both enzymes [51]. PRMT8 was shown to form homodimers and heterodimers with PRMT1 [52]. CARM1 was found to interact with PRMT5 to repress human γ -globin gene expression [53]. PRMT5 was found to interact with PRMT6 to promote colorectal cancer progression [54]. However, the structures, mechanisms, and consequences of those interactions and their downstream effects on gene regulation and cellular processes require substantial investigation. In the

present study, we reported a novel heteromeric interaction between PRMT1 and PRMT6. Remarkably, our new finding showed that PRMT6 acts as a new substrate of PRMT1, and the arginine methylation induced by PRMT1 led to a decrease in the enzymatic activity of PRMT6.

MATERIALS AND METHODS

Cell culture and transfection

About 0.3×10^6 human embryonic kidney 293T cells were seeded in the 6-well culture plate containing 2 mL of 1X Dulbecco's modified Eagle's medium (DMEM, Cellgro) supplemented with 10% Fetal Bovine Serum (FBS, Cellgro) before incubating them at 37 °C with 5% CO₂. When about 80% confluence was reached, 1×10^6 cells were obtained. Transfection was performed using Lipofectamine 3000 (L3000008, Thermofisher) reagent. For the overexpression of PRMT1 or PRMT6, 2.5 µg HA-PRMT1 or Myc-PRMT6 or the mixture of HA-PRMT1 and Myc-PRMT6 was added in 125 µL of Opti-MEM Medium with 5 µL P3000 reagent to get the diluted DNA. 10 µL of Lipofectamine 3000 reagent was diluted by 125 µL of Opti-MEM Medium. Diluted DNA was mixed with diluted lipofectamine 3000 at 1:1 ratio. After 15 minutes, the DNA-lipid complex was added to the cells. For the knock down of PRMT1, 5 µg shPRMT1 or shScramble were incubated with the reagents instead. The mixtures were added into each well of the 6-well plate to transfect HEK293T cells.

Coimmunoprecipitation of PRMT1 and PRMT6

Myc-PRMT6 single-transfected HEK-293T cells or HA-PRMT1 and Myc-PRMT6 co-transfected 293T cells were collected by centrifugation at 1500 rpm at 4°C for 10 min, washed with 1 mL PBS buffer (Cellgro) twice, and lysed in M-PER Mammalian Protein Extraction Reagent (Thermo Scientific) containing 1% protease inhibitor cocktail (Thermo Scientific). The lysate was frozen and thawed once and centrifuged at 12,000 rpm for 20 min. The supernatant was aliquoted with 100 µg protein and immunoprecipitated with (1) 2 µg anti-HA antibody or mouse IgG (Santa Cruz) at 4 °C for 2h followed by 50 µL Protein A/G Plus agarose beads (Santa Cruz) at 4 °C

overnight, or (2) 2 μ g anti-Myc antibody (Origene) or mouse IgG at 4 °C for 2h followed by 50 μ L Protein A/G Plus agarose beads at 4 °C overnight. The beads were washed with 500 μ L TBS buffer with 0.05% Tween-20 for 3 times. The protein on the beads were eluted with SDS loading buffer and separated on 12 % SDS-PAGE. Then the protein bands were immunoblotted with (1) anti-PRMT6 (Santa Cruz) (2) anti-PRMT1 (3) anti-HA antibody or (4) anti-Myc antibody.

Methyltransferase activity of PRMTs

Radioactive methyltransferase assays were conducted to test the methylation of PRMT6 and its activity on histone H3. The reactions were carried out at 30 °C in a reaction buffer containing 50 mmol/L HEPES (pH 8.0), 50 mmol/L NaCl, 1 mmol/L EDTA, and 0.5 mmol/L DTT. 3 μ M PRMT1 or H3.1 (New England Biolabs) or H3.3 (New England Biolabs) together with 20 μ M 14 C-SAM (Perkin Elmer) were incubated with 1 μ M PRMT6 for 1h. Control reaction with only PRMT6 and 14 C-SAM was performed to test its automethylation activity. The reactions were quenched with SDS loading buffer and the methylated products were separated by 12% SDS-PAGE. The radioactive gel was dried and stored for 16 h for a phosphor image scan. The methylated bands were quantified with ImageJ for data analysis.

For characterization of PRMT6 methylation mediated by PRMT1, the varied concentration of PRMT6 (0 ~ 4 μ M) was incubated with 10 μ M 14 C-SAM with 0.2 μ M PRMT1^{WT} or PRMT1^{E153Q} at 30 °C for 1h. For time-dependent PRMT6 methylation assay, 1.5 μ M of PRMT6 and 10 μ M of 14 C-SAM were incubated with 0.4 μ M of PRMT1^{WT} or PRMT1^{E153Q}. The reactions were quenched at different time points (0 ~ 120 min) by SDS loading buffer. The methylation intensity data were normalized according to the reading of 5 μ M 14 C-BSA in liquid scintillation and the PRMT6 automethylation intensity was subtracted from the total PRMT6 methylation intensity in the presence of PRMT1 to derive the data of methylation mediated by PRMT1. For comparison of PRMT6 mutant methylation, 5 μ M of each PRMT6 mutant was incubated with 30 μ M 14 C-SAM with or without 1 μ M PRMT1 at 30 °C for 2h. The methylation intensity data were normalized against PRMT6^{WT}.

Pull down assay of PRMT6

Amylose resin was washed with 5 volumes of column buffer to remove the storage buffer. 20 µg PRMT1 was incubated with the amylose beads under 4 °C for 30 minutes while rotating. The amylose resin with PRMT1 was centrifuged at 500 g for 5 minutes, the supernatant was discarded and the beads were washed by PBS 3 times. After that, 20 µg PRMT6 was incubated with the amylose beads bond with PRMT1 or amylose beads only under 4 °C for 4h while rotating. The resin was centrifuged and washed by PBS 5 times to remove the excess PRMT6 that not binding with PRMT1. The pulled-down proteins were eluted by SDS-PAGE loading buffer and a western blot was performed to detect PRMT1 and PRMT6.

LC-MS/MS analysis of the PRMT6 methylation sites

The methylation sites on PRMT6, either mediated by PRMT1 or by itself, were detected by in-gel digestion and LC-MS/MS analysis following the methylation reaction. 5.5 µM PRMT6 and 200 µM regular SAM were incubated with 1 µM PRMT1 at 30 °C for 3 h in the same reaction buffer as mentioned above. SDS loading dye was added to quench the reaction and 10% SDS-PAGE was conducted to separate the protein. The PRMT6 band was cut from the gel, washed with destaining solution (800 µL), 0.1 M NH₄CO₃ in 50% acetonitrile (400 µL), and 100% acetonitrile (60 µL), and vacuum dried. Then the methylated PRMT6 sample was sent to UAB Proteomics & Mass Spectrometry Facility (Birmingham, AL 35294) for in-gel digestion (Trypsin) and LC-MS/MS detection.

Site-directed mutagenesis of PRMT6

The individually designed primers for the site-directed mutagenesis of potential methylation sites of PRMT6 were synthesized and desalted by Integrated DNA Technologies. The forward and reverse primers are 5'-gaagatggcgcggagaaggaggcgccctggag-3' and 5'-ctccagggccgcctccttctccgcgccatcttc-3' for PRMT6-R29K, 5'-gaactgggcagcactgaaaggcaagacggtactgg-3' and 5'-ccagtaccgtcttgcttccagtgtgcccagttc-3' for PRMT6-R82K, 5'-cccaggccggggccaagcgcgtgtacgcgg-3' and 5'-ccgcgtacacgcgcttggccccggcctggg -3' for PRMT6-R106K, 5'-

ggagggcctt-cgccacgaagtgtctcatgggccactc-3' and 5'-gagtgg-cccatgagacacttcgtggcga-agccctcc-3'. for PRMT6-R228K, 5'-gtccgtcctccacgcgaaaaccaagtggctga-agg-3' and 5'-ccttcagccacttggttttcgctggaggacg-gagc-3' for PRMT6-R174K, 5'-cggtcacgaggagttgatcgcggaccgc -3' and 5'-gcggtccgcgat-caactcctcgtggaccg- 3' for PRMT6-M60L, 5'-ctc-ctgcacgagtcgcgcgtgagctccgtcctc-3' and 5'-gaggacg-gagctcagcgcggactcgtgcaggag-3' for PRMT6-M166A. Mutation of each codon was accomplished by PCR amplification with native pfu polymerase, synthesized primers, and His6×PRMT6-pET28a(+) as a template. Following PCR reactions, Dpn1 was added to digest the original methylated plasmid. Then the plasmid with each mutation was heat-shock transformed to XL1blue super-competent cells, which were selected on agar plates with Kanamycin at 37 °C overnight. The single colonies were picked up and incubated in 4 mL LB media with Kanamycin for 16 h. The mutant DNA was extracted with Wizard Plus SV Minipreps DNA purification system (Promega) and the correct mutations were confirmed by DNA sequencing with Genscript Inc.

Expression and purification of PRMT1, PRMT1 mutant, PRMT6 and PRMT6 mutants

His-tagged PRMT1, MBP-tagged PRMT1, His-tagged PRMT6, and the mutants were expressed by recombinant DNA technology in *E. coli*, and then affinity-purified with Ni-NTA His binding resin (Novagen). PRMT1-pET28b or PRMT6/mutant-pET28a(+) plasmid was transformed into *E. coli* BL21(DE3) (Stratagene) through heat shock. One colony of the bacteria was inoculated into 4 mL LB media containing kanamycin or ampicillin and incubated at 37 °C overnight. The next day, the culture was added to 1 Liter of LB media and incubated until OD₅₉₅ reached 0.6 ~ 0.8. Protein expression was induced with 0.3 mmol/L IPTG (isopropyl β-D-1-thiogalactopyranoside) at 16 °C overnight. After that, the culture was centrifuged at 5000 rpm for 10 min and the cell pellet was resuspended in lysis buffer (25 mmol/L Na-HEPES, pH 8.0, 150 mmol/L NaCl, 1 mmol/L MgSO₄, 5% ethylene glycol, 5% glycerol, and 0.5 mmol/L PMSF). Cell lysis was carried out by high-pressure cell disruptor. The lysate was centrifuged and then the supernatant was loaded onto Ni-NTA beads equilibrated with column buffer (25 mmol/L Na-HEPES (pH 7.0), 300 mmol/L NaCl, 1

mmol/L PMSF, and 30 mmol/L imidazole). Following protein loading, the beads were washed thoroughly with 10 volumes of column buffer and 10 volumes of washing buffer (25 mmol/L Na-HEPES (pH 7.0), 300 mmol/L NaCl, 1 mmol/L PMSF, and 70 mmol/L imidazole), and then the bound protein was eluted with elution buffer (25 mmol/L Na-HEPES (pH 7.0), 300 mmol/L NaCl, 1 mmol/L PMSF, 100 mmol/L EDTA, and 200 mmol/L imidazole). Different eluants were checked on 12% SDS-PAGE gel. Elution fractions with target protein were combined and concentrated with 10,000 MWCO centrifugal filters (Millipore), and then dialyzed against storage buffer (25 mmol/L Na-HEPES (pH 7.0), 300 mmol/L NaCl, 1 mmol/L EDTA, 10 mmol/L DTT and 10% glycerol) at 4 °C. After dialysis, protein concentration was determined using Bradford assay. The final protein samples were aliquoted, flash-frozen, and stored at -80 °C. For each enzymatic assay, a fresh aliquot was melted on ice and diluted to the assay concentration as needed.

Steady-state kinetics characterization of PRMT6 mutants

The steady-state kinetics of selected PRMT6 mutants were also studied in the radioactive assays at 30 °C in the same reaction buffer. The concentration is 0.6 μM for the PRMT6 mutant and 30 μM for ¹⁴C-SAM. Synthesized H3(1-31) peptide (sequence: ARTKQTARKSTGGKAPRKQLATKVARKSAPA) was used as a substrate, the concentration of which ranged from 0 to 200 μM. The reaction was initiated by adding the enzyme once the other components were incubated at 30 °C for 5 min. After continuous incubation for 60 minutes, the reaction was quenched by spreading the reaction mixture onto the surface of the P81 filter paper (Whatman). The paper was washed with 50 mmol/L NaHCO₃ (pH 9.0) and air dried. Then liquid scintillation was performed to quantify the amount of methylated products.

RESULTS

PRMT6 interacts with PRMT1

To investigate potential interactions between different PRMT members, PRMT6 was incubated with one of the other PRMT members in the presence of [³H] SAM. The

reaction mixture was resolved on SDS-PAGE and subjected to autoradiography imaging. We clearly observed PRMT6 underwent automethylation (Figure 1A, lane 3), which coincides with the literature reports [41, 55]. Of surprise, when mixed with PRMT1, the methylation of PRMT6 was significantly augmented (Figure 1A, lane 4). This finding provided the initial evidence that PRMT1 interacted with PRMT6 and methylated the latter.

To validate the interaction between PRMT1 and PRMT6 *in vivo*, HEK293T cells were transfected with *HA-PRMT1* or *Myc-PRMT6*, the cell lysate was extracted after transfection. The anti-Myc antibody or anti-HA antibody was respectively bound to A/G agarose beads then the whole cell lysate was added. The proteins immunoprecipitated by the anti-Myc or anti-HA were eluted and western blot analysis was performed to detect PRMT1 or PRMT6. The result shown in Figure 1B clearly proved that the transfected *Myc-PRMT6* immunoprecipitated endogenous PRMT1 and reciprocally, the transfected *HA-PRMT1* immunoprecipitated endogenous PRMT6 in HEK293T cells. Moreover, in the HEK293T cells co-transfected with *HA-PRMT1*, *Myc-PRMT6* plasmids, *HA-PRMT1* and *Myc-PRMT6* were capable of reciprocally immunoprecipitated each other from the co-transfected cell lysate (Figure 1C).

To further verify a direct physical interaction exists between PRMT1 and PRMT6, MBP pull-down assay was performed *in vitro* using recombinant MBP-tagged PRMT1 protein. MBP-PRMT1 was incubated with amylose beads first and PRMT6 was incubated with the beads after washing. The resin was washed and protein was eluted by SDS-loading buffer. As shown in Figure 1D, PRMT6 was pulled down on MBP-PRMT1-bound amylose resin. Thus, this pull-down analysis supported that there was a direct interaction between PRMT6 and PRMT1.

PRMT6 is methylated by PRMT1

Having known that PRMT1 interacts with PRMT6 *in vitro* and *in vivo*, we next examined more details about the activity of PRMT1 in transferring methyl group(s) to PRMT6 by performing gel electrophoresis autoradiography. The inactive

PRMT1^{E153Q} was expressed and used as a negative control to validate PRMT1 activity on PRMT6 methylation. As displayed in Figure 2A, PRMT6 itself in the presence of ¹⁴C-SAM exhibited automethylation activity of PRMT6, confirming the result in Figure 1A. PRMT6 methylation band was much stronger in the presence of PRMT1^{WT}, but not the inactive E153Q mutant, clearly showing that PRMT6 was a substrate of PRMT1^{WT}. Notably, when histone H3, a substrate of PRMT6, was introduced, the automethylation of PRMT6 diminished significantly (Figure 2A, Lane 4), implying that PRMT6 prefers methylating its histone substrate rather than itself. To further verify PRMT6 methylation by PRMT1, we knocked down the PRMT1 Level in HEK293T cells by shPRMT1 (Figure 2B) and then performed the immunoprecipitation of PRMT6. The result showed that both ADMA and MMA levels in PRMT6 were decreased as a result of PRMT1 knockdown (Figure 2C). Furthermore, we overexpressed PRMT1 in HEK293T cells and immunoprecipitated endogenous PRMT6. The immunoblot clearly showed an increase in the ADMA level in PRMT6 (Figure 2D). These biochemical and cellular assay data collectively demonstrated that PRMT6 was a substrate of PRMT1.

PRMT1-mediated methylation of PRMT6 goes much faster than PRMT6 automethylation

We then sought to further quantify PRMT1-catalyzed PRMT6 methylation and compared this activity with PRMT6 automethylation. PRMT6 methylation level was checked at different time points in the presence of PRMT1^{WT} (Figure 3A). At each time point, we observed that the existence of PRMT1^{WT} led to an increasingly darker ¹⁴C-labeled PRMT6 methylation band. In contrast, under the same condition, PRMT6 methylation level was barely visible at different time points in the presence of PRMT1^{E153Q} which was the inactive form of PRMT1 (Figure 3B). This data further proved that the observed methylation of PRMT6 in Figure 1A was resulted from PRMT1 activity.

Although the automethylation band was not strong when the final concentration of PRMT6 was at 1.5 μ M (Figure 3B), once the concentration of PRMT6 was increased to

4.5 μM , the methylation band became very clear when the incubation time was higher than 30 min (Figure 3C). In addition, the automethylation of PRMT6 appeared to be affected slightly by the addition of PRMT1^{E153Q} (Figure 3C). The quantification of the band intensities of Figure 3A was shown in Figure 3D. We also analyzed PRMT1-catalyzed PRMT6 methylation at different PRMT6 concentrations (Figure 3E). The quantification of band intensities was shown in Figure 3F. PRMT6 automethylation was subtracted from the total methylation to calculate PRMT1-catalyzed methylation. The data were fit with the Michaelis-Menton kinetic equation, yielding k_{cat} of $0.066 \pm 0.009 \text{ min}^{-1}$ and K_m of $0.3765 \pm 0.06 \mu\text{M}$. PRMT6 automethylation activity showed k_{cat} of $0.040 \pm 0.006 \text{ min}^{-1}$ and K_m of $0.1403 \pm 0.05 \mu\text{M}$. Clearly, PRMT6 methylation by PRMT1 is much stronger than PRMT6 automethylation.

The major methylation site in PRMT6 is R106 for PRMT1 catalysis

It is critical to know the residue site(s) in PRMT6 methylated by PRMT1 in order to understand the nature and consequence of this methylation event. Toward this goal, we incubated PRMT6 and SAM together with PRMT1, resolved the mixture on the SDS-PAGE gel, cut out the PRMT6 band and detected the modification sites by LC-MS/MS analysis. From the database search, PRMT6 was identified (Homo sapiens, Gene ID 55170, 41,937.4 Da), with 29 unique peptides, 57 unique spectra, 462 total spectra, and 307/375 amino acids (82% coverage). Two arginine residues were detected to be dimethylated: Arg-82 and Arg-174, and three arginine residues were detected to be mono-methylated: Arg-29, Arg-106, and Arg-228 (Figure 4A and 4B).

To confirm these methylation sites in PRMT6, we generated several mutants, PRMT6^{R29K}, PRMT6^{R82K}, PRMT6^{R106K}, PRMT6^{R174K} and PRMT6^{R228K}, by performing site-directed mutagenesis. A previous study showed that PRMT1 has two important conserved methionine residues and both PRMT1^{M48L} and PRMT1^{M155A} mutants showed an automethylation activity compared to wild-type PRMT1 [56]. These results indicated that M48 and M155 are important for PRMT1 substrate recognition and relevant to the automethylation activity of mutant PRMT1. Thus, the two corresponding mutations in

PRMT6, i.e. PRMT6^{M60L} and PRMT6^{M166A}, were also generated for the following tests. The mutants were expressed as his6x-tagged proteins in *Escherichia coli* (*E. coli*) BL21(DE3) and purified with Ni-charged affinity chromatography. All the mutants were tested in the radioactive autography assay for detecting their methylation levels. Two sets of methylation tests, with and without PRMT1, were run in parallel, so that the automethylation can be subtracted from the total methylation to obtain the PRMT1-mediated methylation (Figure 5A, 5B).

Compared to wt-PRMT6, PRMT6^{R106K} mutant showed significantly weaker methylation by PRMT1 (~23% methylation left) but still underwent automethylation. On the other hand, PRMT6^{R174K} mutant retained ~80% PRMT1-catalyzed methylation but showed little automethylation activity (~4% methylation left). This indicates that R106 is likely the major targeting site for PRMT1, but not a major PRMT6 automethylation site. On the other hand, R174 may be the major automethylation site in PRMT6, but not a major PRMT1-mediated methylation site. It might also be possible is that R174 was critical for PRMT6 catalysis and thus R174K mutation compromised its enzymatic activity. PRMT6^{R82K}, unexpectedly, showed equal PRMT1-catalyzed methylation and even higher automethylation. In addition, M60L methylation by PRMT1 was lowered to ~33% and M166A automethylation was decreased to ~38%, indicating their moderate roles in these two types of methylation processes.

Methylation by PRMT1 regulates the enzymatic activity of PRMT6

To determine the possible effect of arginine methylation on PRMT6 by PRMT1, selected mutants were tested for their differences in methyltransferase activity on H3(1-31) peptide. The Michaelis-Menton kinetic curves and catalytic parameters for each mutant were compared in Figure 6A and Table 1. PRMT6^{WT} had a k_{cat} of 0.0063 ± 0.0006 min⁻¹ and a K_m of 8.4 ± 0.7 μ M. Notably, PRMT6^{R106K} which was a poor substrate of PRMT1 showed ~2-fold increase in turnover rate ($k_{cat} = 0.0122 \pm 0.0004$ min⁻¹) compared with PRMT6^{WT}. This raised the possibility that PRMT1-mediated methylation on R106 suppressed the activity of PRMT6. To confirm the effect of PRMT1 on PRMT6 activity,

radioactive gel methylation assay was performed with PRMT6 being incubated with histone H3 and varying concentrations of PRMT1^{WT}. The result showed that as the PRMT1 amount increased, the PRMT6 methylation level increased while histone H3 methylation level decreased gradually (Figure 6B). Additionally, we analyzed the level of H3R2 methylation, a key target of PRMT6, in HEK293T cells transfected with the HA-PRMT1 plasmid. Immunoblotting of the cell lysate showed that H3R2me2a level was appreciably lower in the PRMT1 overexpressed cells (Figure 6C). These data together demonstrated that PRMT1-mediated methylation of PRMT6 suppressed the enzymatic activity of PRMT6 on H3 substrate. Notably, PRMT6^{R174K} gave no detectable activity on H3 methylation which means R174 is critical for PRMT6 catalytic activity and coincides with that R174K mutation abolishes its automethylation activity as well (Figure 6A). PRMT6^{M60L} and PRMT6^{M166A} mutations also lowered the activity of PRMT6 significantly. Overall, methylation of PRMT6 at the major site R106 induced by PRMT1 negatively regulates PRMT6 enzymatic methyltransferase activity.

Inspired by the previous work which had demonstrated the interaction between PRMT1 and PRMT2 affects PRMT1 enzymatic activity, we wondered if the interaction between PRMT1 and PRMT6 affects PRMT1 enzymatic activity or not. For this purpose, PRMT1 was incubated with inactive PRMT6^{VLD:KLA} mutant, and then histone H4 was added. As showed in Figure 6D, H4 methylation band intensity was constant as PRMT6 concentrations were varied. Thus, PRMT6 did not affect PRMT1 activity.

DISCUSSION

PRMT enzymes interact with various cellular proteins to regulate biological processes such as gene transcription, DNA repair, and RNA splicing and signal transduction [10, 57]. In particular, a few studies have shown the probability that one PRMT interacts with another member in the PRMT family, forming heterological complexes. Pak *et al* [51] demonstrated the formation of a heterodimer between PRMT1 and PRMT2, which increases PRMT1 enzymatic activity. Chen *et al* [54] showed that PRMT5 is an interactive partner of PRMT6, and PRMT6 functionally associates with

PRMT5 to promote the progression of colorectal cancer by downregulating the expression of CDKN2B and CCNG1. A recent study showed that CARM1 interacts with PRMT5 and PRMT5 is methylated by CARM1 at R505 [53]. In the current work, we demonstrated PRMT1 interacts with PRMT6 and methylates PRMT6. In the course of our studies, a recent study by Schneider *et al* [58] found that PRMT1 was co-precipitated with PRMT6, which is in good agreement with this work. The intricate interplay between PRMTs could be a common biochemical strategy that eukaryotic cells utilize to fine tune enzymatic activities of these enzymes for arginine methylation control on the global scale as well as on specific proteins.

In our immunoprecipitation experiments, PRMT1 and PRMT6 were reciprocally pulled down from the co-transfected as well as single-transfected cells. The interaction between PRMT1 and PRMT6 hint at that multiple heterological interactions may exist between different PRMT isoforms. When using eukaryotic systems to express PRMTs, caution should be taken that one or more other PRMT family members may be co-eluted, complicating the subsequent enzymatic activity analysis.

A few PRMT family members have been demonstrated to undergo automethylation, including PRMT1 mutants M48L and M155A, CARM1, PRMT6, and PRMT8 [41, 56, 59, 60]. Among these PRMTs, PRMT6 has been reported to methylate itself at site R35 [41]. In our study, PRMT6 methylation level was significantly enhanced by the addition of PRMT1. To substantiate PRMT1-catalyzed PRMT6 methylation, we compared PRMT6 total methylation with the automethylation. The presence of PRMT1^{WT} rather than the inactive PRMT1^{E153Q} mutant significantly enhanced the methylation level of PRMT6, demonstrating that PRMT6 is a novel substrate of PRMT1. Our quantitative catalytic rate measurements showed that 0.4 μ M PRMT1 was able to accelerate the methylation rate of 5 μ M PRMT6 by ~4 fold. It is conceivable to speculate that PRMT1 may be largely responsible for the observed PRMT6 methylation in mammalian cells wherein PRMT1 acts as the predominant arginine methyltransferase *in vivo*. PRMT1-catalyzed PRMT6 methylation showed a K_m of $1.5 \pm 0.6 \mu$ M, comparable to that of PRMT1-H4 interaction ($K_m = 1.69 \pm 0.39 \mu$ M [61]).

LC-MS/MS analysis of methylated PRMT6 by PRMT1 exhibited high sequence coverage and identified five target arginine residues. Among those residues, R106 was found as the major PRMT1-mediated methylation site through the site-directed mutagenesis study (Figure 5B). Additionally, R29 seemed to be slightly methylated by PRMT1. However, no significant changes in PRMT1-mediated methylation were observed for R82K, R174K and R228K. Notably, R106 was not the automethylation site since PRMT6^{R106K} still retains similar automethylation level as the PRMT6^{WT}. The steady-state kinetic measurement showed no detectable methylation activity of R174K on the H3 peptide (Figure 6). This suggests that either the R174 residue or methylation of R174 is essential for PRMT6 activity. A previous study showed that PRMT6 automethylation occurred at R29, R35, and R37, with R35 confirmed as the automethylation site regulating PRMT6 stability [62]. However, in our study, R35 was not identified as a methylation site by LC-MS/MS. Nevertheless, we showed that R29 is not a major methylation site since PRMT6^{R29A} still exhibited similar automethylation level as PRMT6^{WT} and R29 was still efficiently methylated by PRMT1. Further investigation is required to determine the other automethylation site(s) on PRMT6 and their effects.

According to the sequence alignment, PRMT1 and PRMT6 have reasonably high sequence similarity (54% positives). The corresponding sites of R82, R106, R174, R228 in PRMT6 are conserved as K70, R94, R163, K215 in PRMT1, respectively (Figure 7). R29 is on the flexible N-terminal tail of PRMT6. It is interesting to see that R106 and R174 of PRMT6 are methylated but methylation of the corresponding residues R94 and R163 of PRMT1 are not found. In the crystal structure of PRMT6, R106 (aligned with R94 of PRMT1) is located on the surface loop connecting helix A and strand 2 of the SAM-binding domain. The flexibility of this loop region may make R106 of PRMT6 accessible to the active site of PRMT1. R174 (aligned with R163 of PRMT1) is located on Helix D and faces the interface between the SAM-binding domain and the barrel-like domain. Likely R174 on PRMT6 is important for maintaining the α -helix structure which is critical for catalysis.

From a biochemical perspective, methylation of arginine residues can introduce steric hindrance of the guanidino group and compromise its H-bonding capacity, thus altering protein local structure or protein-protein interaction or regulating the enzymatic activity. PRMT6-R106K, which significantly lost PRMT1-mediated methylation compared to PRMT6-WT, showed a 2-fold increase in its catalytic activity (Figure 6), highlighting that PRMT1-mediated methylation suppresses the enzymatic activity of PRMT6. Indeed, the quantitative biochemical assays showed that PRMT1-mediated PRMT6 methylation significantly decreased the enzymatic activity of PRMT6 on its substrate histone H3. Further, cellular assays showed that PRMT1 overexpression suppressed H3R2 methylation, an important cellular target of PRMT6. Interestingly, a previous study showed that PRMT6 automethylation is important for its stability and its activity which is involved in inhibiting HIV-1 replication [62]. Therefore, PRMT1-mediated PRMT6 methylation and PRMT6 itself-mediated automethylation have opposite effects on PRMT6 activity. Our results support that PRMT1 counteracts both PRMT6 automethylation activity and its histone substrate methylation activity. This observation may be physiologically significant. It is known that PRMT1 activates transcription but PRMT6 represses transcription [37]. Based on our finding, we propose that PRMT1 regulates transcriptional regulation on the chromatin through dual mechanisms: direct action of histone methylation and repressive methylation of PRMT6. Thus, PRMT1's impact on transcription extends beyond its primary histone methylation function, fine-tuning gene expression is further achieved by counteracting the activity of a repressive transcriptional cofactor, i.e. PRMT6. The previous research has identified a number of gene targets regulated by PRMT6. For instance, PRMT6 downregulates tumor suppressor genes p53, p21, p16 and p27 through the generation of H3R2me2a marks [63-66]. PRMT6 is capable of downregulating *HOXA* genes [67]. In the U2OS cells, PRMT6 is shown to repress the expression of TSP-1 [32]. Furthermore, the presence of the H3R2me2a mark impedes the recognition of the H3K4me3 modification by reader proteins [38]. Of great interest, Choi *et al* [68] recently observed the suppressive effect of

PRMT1 on PRMT6 in skeletal muscle and myoblasts, which is well in line with our results.

CONCLUSION

In conclusion, this current investigation presented a new finding about the interaction between two important PRMT members PRMT1 and PRMT6, and intriguingly, PRMT6 was shown to be a novel substrate of PRMT1. We identified specific arginine residues of PRMT6 that are methylated by PRMT1, with R106 being the major methylation site. Combined biochemical and cellular data showed that PRMT1 downregulates the enzymatic activity of PRMT6 in histone H3 methylation. Understanding the intricate interplays between PRMT1 and PRMT6 will be crucial for deciphering the complex regulatory networks governing gene expression. Future research is warranted to elucidate whether and how various signaling pathways regulated by PRMT6 can be counteracted by PRMT1. Priority should be given on the examination of functional consequences of PRMT6 methylation mediated by PRMT1 on different protein substrates and in different biological contexts.

ARTICLE HIGHLIGHTS

Research background

Post-translational modifications (PTMs) play key roles in various biological processes. Protein arginine methyltransferases (PRMTs) transfer the methyl group to specific arginine residues. Both PRMT1 and PRMT6 have emerged as crucial factors in the development and progression of multiple cancer types. We posit that Protein arginine methyltransferase 1 (PRMT1) and Protein arginine methyltransferase 6 (PRMT6) might interplay directly or in-directly in multiple ways accounting for shared disease phenotypes.

Research motivation

The tumor-promoting roles of PRMT1 and PRMT6 in oncology are executed through their methylation of histone and non-histone substrates. Expression profile analysis suggests that PRMT1 and PRMT6 are both involved in multiple pathways which are fundamental for cell proliferation. We posit that PRMT1 and PRMT6 might interplay directly or in-directly for shared disease phenotypes. Thereby, neutralizing these enzymes' activities or their interactions may interfere with tumor progression and lead to anticancer beneficial effects.

Research objectives

Understanding the role and function of PRMTs and how they interact with each other, identification of the methylation site(s) on PRMT6. Knowing the mechanism of this intercommunication will help develop inhibitor of tumor progression and increase cancer therapeutic effect. Knowing the interaction between PRMT1 and PRMT6 regulate the enzymatic activity of PRMT6.

Research methods

Gel electrophoresis autoradiography was performed to test the methyltransferase activity of PRMTs and characterize the kinetics parameters of PRMTs. LC-MS/MS analysis was performed to detect the PRMT6 methylation sites.

Research results

In this study we investigated the interaction between PRMT1 and PRMT6, and PRMT6 was shown to be a novel substrate of PRMT1. We identified specific arginine residues of PRMT6 that are methylated by PRMT1, with R106 being the major methylation site. Combined biochemical and cellular data showed that PRMT1 downregulates the enzymatic activity of PRMT6 in histone H3 methylation.

Research conclusions

PRMT6 is methylated by PRMT1 and R106 is a major methylation site induced by PRMT1. PRMT1 methylation suppresses the activity of PRMT6.

Research perspectives

Future research is warranted to elucidate whether and how various signaling pathways regulated by PRMT6 can be counteracted by PRMT1. Priority should be given on the examination of functional consequences of PRMT6 methylation mediated by PRMT1 on different protein substrates and in different biological contexts.

4

ACKNOWLEDGEMENTS

We thank the National Institutes of Health for supporting this work (grant #R01GM126154 and 1R35GM149230).

2%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.mdpi.com Internet	38 words — 1%
2	Thiebaut Charlène, Eve Louisane, Poulard Coralie, Muriel Muriel. "Structure, Activity, and Function of PRMT1", Life, 2021 Crossref	35 words — 1%
3	scholarworks.gsu.edu Internet	35 words — 1%
4	Tyler Brown, Terry Nguyen, Bo Zhou, Y. George Zheng. "Chemical probes and methods for the study of protein arginine methylation", RSC Chemical Biology, 2023 Crossref	15 words — < 1%

EXCLUDE QUOTES ON

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE SOURCES

EXCLUDE MATCHES

< 12 WORDS

< 12 WORDS